Editorial: A perspective on the American heart association/American college of cardiology science advisory on thiazolidinedione drugs and cardiovascular risks

Circulation: Cardiovascular Quality and Outcomes

Volumn 3, Issue 3, 2010, Pages 221-222

  Krumholz, Harlan M ^a,b,c  

^a Robert Wood Johnson Clinical Scholars Program   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c YALE NEW HAVEN HOSPITAL   (United States)

Author keywords

Cardiovascular risks; Editorials; Thiazolidinedione drugs

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ADVANDIA; GLYCOSYLATED HEMOGLOBIN; METFORMIN; MURAGLITAZAR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PIOGLITAZONE; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; 2,4 THIAZOLIDINEDIONE; 2,4-THIAZOLIDINEDIONE; ANTIDIABETIC AGENT;

CARDIOVASCULAR RISK; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; EDITORIAL; GLYCEMIC CONTROL; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MEDICAL SOCIETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; SIDE EFFECT; ADVISORY COMMITTEE; CARDIOVASCULAR DISEASE; DRUG CONTRAINDICATION; EVIDENCE BASED MEDICINE; NON INSULIN DEPENDENT DIABETES MELLITUS; UNITED STATES;

ADVISORY COMMITTEES; AMERICAN HEART ASSOCIATION; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; EVIDENCE-BASED MEDICINE; HUMANS; HYPOGLYCEMIC AGENTS; PRACTICE GUIDELINES AS TOPIC; THIAZOLIDINEDIONES; UNITED STATES;

EID: 77953439760     PISSN: 19417713     EISSN: 19417705     Source Type: Journal    
DOI: 10.1161/CIRCOUTCOMES.110.936070     Document Type: Editorial

References (11)

1. Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129-139.
2. Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545-2559.
3. The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560-2572.
4. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH. Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation. 2010;121:1868-1877.
5. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA. 2005;294:2581-2586.
6. United States Food and Drug Administration. Safety alert for human medical products: Avandia (rosiglitazone). Available at: http://www.fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm150831. htm. Accessed December 31, 2009.
7. Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med. 2007;356:2457-2471.
8. Drazen JM, D'Agostino RB, Ware JH, Morrissey S, Curfman GD. Ezetimibe and cancer: an uncertain association. N Engl J Med. 2008;359:1398-1399.
9. United States Food and Drug Administration. Drug safety and availability: follow-up to the August 2008 early communication about an ongoing safety review of ezetimibe/simvastatin (marketed as Vytorin), simvastatin (marketed as Zocor) and ezetimibe (marketed as Zetia): FDA investigates a report from the SEAS trial. Available at: http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm194964.htm. Accessed December 31, 2009.
10. Ross JS, Madigan D, Hill KP, Egilman DS, Wang Y, Krumholz HM. Pooled analysis of rofecoxib placebo-controlled clinical trial data: lessons for postmarket pharmaceutical safety surveillance. Arch Intern Med. 2009;169:1976-1985.
11. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation. 2003;108:2941-2948.